
HSDD drug options: Weighing cost, interactions, and nausea
Treating hypoactive sexual desire disorder means matching therapy to each contributing factor, according to Holly N. Thomas, MD, MS.
Management of hypoactive sexual desire disorder (HSDD) should mirror the biopsychosocial framework used to evaluate it, according to Holly N. Thomas, MD, MS, an associate professor of medicine at the University of Pittsburgh Medical Center in Pennsylvania. Contributing factors identified across the medical, psychological, relational, and sociocultural domains are each addressed directly. Relationship discord warrants referral to a sex-positive sex therapist or couples counselor.
Ob-gyns are essential partners in this process, particularly for conditions outside the scope of general internal medicine. Thomas notes that, as a general internist, she may not have the proper skill set to manage certain contributing conditions on her own. Pelvic organ prolapse, for example, could affect sexual function and is best comanaged with urogynecology colleagues, according to Thomas.
Two FDA–approved medications are available for HSDD in women in the United States: flibanserin (Addyi) and bremelanotide (Vyleesi). Non–FDA-approved options include transdermal testosterone. Small studies have suggested a possible role for bupropion, buspirone, and sildenafil, although Thomas emphasizes that these agents have not been approved for this purpose and have been evaluated only in relatively small studies.
Each option carried practical limitations. Flibanserin and bremelanotide could be costly for patients whose insurance plans did not cover them. Flibanserin has potential drug interactions, making a thorough review of the patient’s current medications essential before prescribing. It could also cause dizziness or hypotension, particularly when combined with alcohol, so patients should be counseled not to drink within 2 hours of a dose. For patients already prone to low blood pressure or dizziness, flibanserin may not be the best choice. With bremelanotide, approximately 40% of users experienced nausea in randomized controlled trials.¹
Transdermal testosterone poses a different challenge.
“There’s not a female-specific FDA-approved formulation here in the United States, so if a practitioner is choosing to utilize transdermal testosterone for HSDD in a woman, they have to either rely on compounded products or attempt to titrate small doses of male-formulated products,” Thomas said.²
On the question of which clinician should manage HSDD, Thomas recommends that patients start with whomever they felt most comfortable. A primary care practitioner who is open to the conversation could start the evaluation and make appropriate referrals, even without specific expertise in sexual medicine.
Gynecologists, however, should still be prepared to manage the condition.
“I do think that it’s important for gynecologists to have at least some knowledge and ability to manage hypoactive sexual desire disorder, because estimates are that this affects about 10% of women,” Thomas said. Given how common the condition is, primary care physicians and gynecologists could serve as partners with complementary skill sets in managing it, according to Thomas.
REFERENCES
1. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899-908. doi:10.1097/AOG.0000000000003500
2. Davis SR, Baber R, Panay N, et al. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. doi:10.1210/jc.2019-01603
Related to this article







